Background: Long-standing congestive heart failure can induce a constellation of histopathology changes in the liver that can range from mild sinusoidal dilation to advanced fibrosis and loss of normal perivenular expression of glutamine synthetase (GS). Liver biopsies might be performed to assess the perioperative risk of these patients or to determine the need of synchronous liver transplant. We aimed to assess interobserver agreement in recognizing these liver histologic features in patients undergoing evaluation for heart transplantation and to examine whether immunohistochemistry of GS will aid the diagnosis of cardiac hepatopathy (CH).
Introduction
Liver pathology in patients with congestive heart failure is known as cardiac hepatopathy (CH) or "nutmeg liver" which was initially described by Sherlock in 1951 in liver necropsy specimens [1] . It was characterized by sinusoidal dilatation and centrilobular hepatocyte necrosis. Later on, several studies further described these histologic findings in post-mortem liver specimens from patients with various cardiac diseases or shock, including centrilobular congestion, with or without necrosis, inflammation, sclerosis, and regenerative hyperplasia [2] [3] [4] . With the increasing use of heart transplant in the treatment of heart failure, liver biopsies are increasingly performed to assess the perioperative risk of these patients or to determine the need of synchronous liver transplant. Several studies suggested that chronic CH seems to be a benign, potentially reversible disease [5] . Myers et al reported that elevated right atrial pressure and hepatic venous pressure were associated with the presence of centrilobular necrosis, inflammation, and sinusoidal dilation, but not with hepatic fibrosis [6] . Thus, staging liver biopsies in this type of clinical setting is challenging, although progression to advanced-stage disease (cardiac cirrhosis) remains rare despite the common manifestation of [2, 6] . Recently, one study proposed a congestive hepatic fibrosis score (CHFS) as a novel histologic assessment of clinical severity [7] . However, the interobserver agreement of this scoring system has not been tested in clinical setting. Hepatic injury caused by severe heart failure usually results from prolonged recurrent congestion and/or impaired arterial perfusion. Hepatic injury is associated with biochemical alterations. For example, in normal human liver, glutamine synthetase (GS) is expressed in a rim of hepatocytes surrounding hepatic veins. GS expression is decreased in cirrhosis and efferent venous flow impairment and increased in chronic hepatitis, and focal nodular hyperplasia [8, 9] . Decreased perivenular GS expression was reported in seven of seven liver specimens (100%) from patients with congestive heart failure [9] , suggesting that the loss of perivenular GS can be used as a marker for CH. In addition, six (of seven) showed focal mild to moderate increase in GS positive hepatocyte progenitor cells (HPCs) [9] .
We aimed to assess interobserver agreement in recognizing these liver histologic features in patients undergoing evaluation for heart transplantation and to examine whether immunohistochemistry of GS will aid the diagnosis of CH.
Methods
Medical records at the Cleveland Clinic were searched for patients diagnosed with congestive heart failure from January 2000 to February 2015. Hematoxylin-eosin and trichromestained slides from 36 cases were retrieved and assessed by four liver pathologists. A consensus for each feature is defined as an interpretation agreed upon by three out of four pathologists. The adequacy of the biopsy specimen is defined as biopsy length of at least 1.5 cm. All cases that were analyzed meet the criteria. Histologic features of congestive hepatopathy and other common liver histologic parameters were reviewed, including evaluation of the overall fibrosis (stage) using a recently developed CHFS [7] (Table 1) . Briefly, based on the pattern of fibrosis, scores of 0, 1, 2A, 2B, 3, and 4 were assigned as follows: score 0, no fibrosis; score 1, central fibrosis; score 2A, central zone and portal fibrosis, with accentuation of fibrosis in the central zone; score 2B, moderate portal fibrosis and central zone fibrosis, with accentuation of fibrosis in the portal zone; score 3, bridging fibrosis; score 4, cirrhosis.
Twenty-four liver biopsies were selected with a consensus diagnosis of CH and were stained with GS. Eight liver biopsies with no significant pathological changes from normal donor liver were included as controls. Immunohistochemistry for GS was performed on whole tissue section from formalin-fixed and paraffin-embedded tissue according to manufacturer's instructions using an automatic stainer (Benchmark, Ventana, Tucson, AZ, USA). Briefly, de-paraffinized tissue sections were stained with antibodies against GS (clone GS-6, at 1:500 working dilution; Millipore, Billerica, MA, USA) after antigen retrieval for 30 min using CC1 buffer (Ventana). We used diaminobenzidine as the chromogen. Appropriate positive and negative controls were reviewed. All immunohistochemical stains were evaluated by two pathologists (XL and BH) under a multiheaded microscope. Normal GS expression was defined as a rim of 2 -3 layers of strongly positive hepatocytes around the hepatic veins (perivenular pattern). Absence of GS in the perivenular region was considered abnormal in this study. Immunoreactivity of GS in other regions was not assessed.
Fleiss' kappa was used to assess the interobserver agreement on each histologic feature and CHFS. A kappa value < 0, 0.01 -0.20, 0.21 -0.40, 0.41 -0.60, 0.61 -0.80, and 0.81 -1.0 is considered poor, slight, fair, moderate, substantial, and almost perfect agreement, respectively [10] . Kendall's taub correlation tests were performed to determine the correlation coefficients between histologic features of CH and the loss of perivenular GS immunoreactivity. A P-value < 0.05 was considered statistically significant. Statistical analysis was performed using R 2.15.2 (R Development Core Team, 2012, Vienna, Austria).
Results
A total of 36 liver biopsies taken from patients with clinically and radiographically confirmed congestive heart failure were subjected to detailed histology review by four liver pathologists for the features listed in Table 1 and using criteria described previously [7] . When there was no consensus for a feature, it was categorized as indeterminate. In this cohort, 72% of cases had sinusoidal dilation, 69% centrilobular fibrosis, 58% hepatocyte atrophy, and 47% centrilobular hemorrhage (Figs. 1 and 2), consistent with previous studies that sinusoidal dilation, centrilobular hepatocyte atrophy, fibrosis and hemorrhage were the most common findings in CH. Steatosis is only rare finding as 94% cases showed no steatosis or less than 5% of steatosis. Hepatocyte ballooning and cholestasis was noted in one case (3%) each. Mononuclear inflammation was observed in the portal triads and lobules in 53% and 36% of biopsies. Ductular proliferation was noted in 36% of cases. Five cases had no fibrosis, while the remaining cases showed variable fibrosis including central zone fibrosis only (n = 4, 11%), centrilobular and portal fibrosis with accentuation in central zone (n = 6, 17%), centrilobular and portal fibrosis with accentuation in portal zone (n = 5, 14%), bridging fibrosis (n = 6, 17%), cirrhosis (n = 4, 11%) and fibrosis of indeterminate degree (n = 6, 17%). The consensus histologic data are shown in Table 2 .
A fair-to-good level of interobserver agreement was reached among four reviewers on histopathological features (Table 3) . Evaluation of sinusoidal dilatation had substantial interobserver agreement (0.66, 95% CI: 0.41 -0.86). The other features, centrilobular hepatocyte atrophy, centrilobular fibrosis, and centrilobular hemorrhage only had moderate to fair interobserver agreement. The overall agreement on the diagnosis of CH and CHFS was moderate (K = 0.55, 95% CI: 0.32 -0.73) and fair (K = 0.35, 95% CI: 0.24 -0.49), respectively. When the fibrosis stage is simplified into advanced (3 and 4) versus no or non-advanced fibrosis (0 -2B), the interobserver agreement improved to moderate (K = 0.45, 95% CI: 0.31 -0.61).
Twenty-four liver biopsies had consensus diagnosis of CH and were subjected to immunohistochemistry for GS. All eight control cases showed strong perivenular GS staining. Twelve cases of CH showed retained and 12 cases of CH showed loss of the normal perivenular GS staining (Fig. 3) . Histologic features of CH (presence of sinusoidal dilation, centrilobular hepatocyte atrophy, hemorrhage, and centrilobular fibrosis) and the stage of fibrosis (CHFS) did not correlate with the loss of normal GS staining pattern (Table 4) .
Discussion
Congestive hepatopathy or CH is a common condition associated with chronic elevation of right heart pressure as a result of chronic congestion with or without superimposed decrease in hepatic arterial perfusion [11] . Original characterization of histologic features of congestive hepatopathy was performed in necropsy or post-mortem specimens. The more widespread use of heart transplantation as a treatment for end stage of heart disease and the potential reversibility of congestive hepatopathy are associated with increased frequency of liver biopsies to assess the perioperative risk of these patients and/or to determine the need of synchronous liver transplant. However, large series of liver biopsies from patients with congestive heart failure are lacking. Our study of 36 liver biopsies from patients with clinically and radiographically documented congestive heart failure revealed a spectrum of histology. The most common histologic finding in our series included sinusoidal dilation (72% of cases), centribular fibrosis (69% of cases), hepatocyte atrophy (58% of cases), and centrilobular hemorrhage (47% of cases). In addition, our study revealed the presence of mononuclear inflammation in the portal tracts and lobules in approximately 53% and 36% of cases, respectively. The overall finding is consistent with previous reports [1] [2] [3] [4] 7] . In line with previous observations, only four of 36 (11%) liver biopsies from our cohort of congestive heart failure showed cirrhosis [2, 6] . One previous study proposed a CHFS as a novel histologic assessment of clinical severity [7] . However, the CHFS has not been studied for its interobserver variability. Our study revealed that the overall agreement on the diagnosis of CH and CHFS was moderate (K = 0.55, 95% CI: 0.32 -0.73) and fair (K = 0.35, 95% CI: 0.24 -0.49), respectively. However, if the staging is simplified into advanced (bridging or cirrhosis) and/or non-advanced fibrosis, the interobserver agreement is improved to moderate category (K = 0.45, 95% CI: 0.31 -0.61). Among the common features of CH, sinusoidal dilatation showed substantial interobserver agreement, followed by centrilobular hepatocyte atrophy and fibrosis (moderate agreement), and centrilobular hemorrhage (fair agreement).
One interesting finding is the low rate of steatosis in CH as 94% of CH had no steatosis or less than 5% steatosis in our study, lower than general population and young adults in the United States [12] [13] [14] . Whether this is related to the patient's overall nutrition status or due to impaired triglyceride synthesis in hepatocytes due to congestion with or without superimposed hepatic arterial perfusion remains unclear. Similarly, hepatocyte ballooning, Mallory hyalines, cholestasis, and neutrophilic inflammation are only rarely observed in CH. The presence of these features should prompt searching for other etiologies such as alcohol, sepsis, biliary obstruction, and drug-induced liver injury.
As one small study previously suggested a potential use of GS in the diagnosis of CH [9] , we performed immunohistochemistry of GS on a cohort of histologically confirmed cases of CH. In contrast to the previous study, only 50% (12 out 24) of our cases had decreased perivenular GS expression. This may be due to stage difference and specimen type (100% biopsy in the current study versus 75% (eight of 12) biopsy), use of different antibody, and cutoff value. Regardless, significant loss of perivenular GS expression may be a marker for CH, but only with a sensitivity of 50%. Interestingly, the loss of perivenular GS expression was not associated with the features we examined which include sinusoidal dilatation, centrilobular atrophy, centrilobular hemorrhage, and centrilobular fibrosis, and fibrosis (CHFS).
One of the main strengths of this study is that it is one of the largest cohorts of patients with CH from a single institute and all cases were confirmed clinically and radiographically. In addition, 24 cases of CH used for GS immunohistochemical study were agreed upon by at least three out of four liver pathologists who were GI and liver pathology fellowship trained and are actively practicing liver pathology.
There are limitations to our study. While these CH cases were clinically confirmed, the histology results including the CHFS were not correlated with detailed clinical features and demographics, lab test results, and the patients' outcome. The CH population in this cohort may be different from the cohort in previous studies or from other institutes as these cases were seen in our tertiary hospital before heart transplantation and our patients may potentially have more severe disease. In addition, this study only involves four liver pathologists and no general pathologists without liver pathology fellowship training were included in this study.
In summary, we examined for the first time, the interobserver variability on several previously reported important histologic features of CH in a clinical practice outside of research setting. A CHFS could only be assigned with a fair level of agreement (kappa value of 0.35) in our study. Our data reaffirm the significant interobserver variability in liver biopsy interpretation in CH even among liver pathologists. Simplification of stage into advanced (bridging and cirrhosis) and nonadvanced fibrosis results in moderate interobserver agreement (kappa value of 0.45). Our current results suggest that implementing this scoring system can be challenging, especially for early stages of CH.
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